These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38001033)

  • 61. The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma.
    Park IK; Hyun K; Kim ER; Park S; Kang CH; Kim YT
    Eur J Cardiothorac Surg; 2018 Dec; 54(6):1022-1027. PubMed ID: 29878144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
    Liu X; Li X; Zhang C; Jin J; Wang Z; Xiao R; Sun K; Wang J; Zhong W; Yang F
    Lung Cancer; 2022 May; 167():78-86. PubMed ID: 35427848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
    Suda K; Ohara S; Fujino T; Hamada A; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    Clin Lung Cancer; 2022 Jan; 23(1):e60-e68. PubMed ID: 34750065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.
    Villaruz LC; Wang X; Bertino EM; Gu L; Antonia SJ; Burns TF; Clarke J; Crawford J; Evans TL; Friedland DM; Otterson GA; Ready NE; Wozniak AJ; Stinchcombe TE
    ESMO Open; 2023 Apr; 8(2):101183. PubMed ID: 36905787
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical usefulness of the 3-tier classification according to the proportion of morphological patterns for patients with pathological stage I invasive lung adenocarcinoma.
    Osawa J; Shimada Y; Maehara S; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Matsubayashi J; Ikeda N
    Gen Thorac Cardiovasc Surg; 2021 Jun; 69(6):943-949. PubMed ID: 33385289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Solid Components in the Mediastinal Window of Computed Tomography Define a Distinct Subtype of Subsolid Nodules in Clinical Stage I Lung Cancers.
    Yin J; Xi J; Liang J; Zhan C; Jiang W; Lin Z; Xu S; Wang Q
    Clin Lung Cancer; 2021 Jul; 22(4):324-331. PubMed ID: 33789831
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma.
    Han X; Fan J; Li Y; Cao Y; Gu J; Jia X; Wang Y; Shi H
    Sci Rep; 2021 Mar; 11(1):5679. PubMed ID: 33707479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis.
    Matsumura Y; Owada Y; Yamaura T; Muto S; Osugi J; Hoshino M; Higuchi M; Ohira T; Suzuki H; Gotoh M
    Interact Cardiovasc Thorac Surg; 2016 Aug; 23(2):216-22. PubMed ID: 27173985
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Xiong A; Li C; Xu J; Yang X; Nie W; Zhong H; Chu T; Zhang W; Zhong R; Pan F; Shen Y; Lou Y; Zhang B; Han B; Zhang X
    Lung Cancer; 2021 Apr; 154():124-130. PubMed ID: 33657514
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
    Lee YJ; Park IK; Park MS; Choi HJ; Cho BC; Chung KY; Kim SK; Chang J; Moon JW; Kim H; Choi SH; Kim JH
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1647-54. PubMed ID: 19517135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
    BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Cao Y; Xu H; Liao M; Qu Y; Xu L; Zhu D; Wang B; Tian S
    Int J Clin Oncol; 2018 Apr; 23(2):249-257. PubMed ID: 28988295
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.
    Inoue T; Matsumura Y; Araki O; Karube Y; Maeda S; Kobayashi S; Chida M
    Ann Thorac Cardiovasc Surg; 2018 Feb; 24(1):1-5. PubMed ID: 29093430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
    Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
    Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.